Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934555 · ClinicalTrials.gov registry record · Phase 2
Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
A Phase 2 study of Cardiac Arrest, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02934555 is a Phase 2 study of Cardiac Arrest that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 48 participants, below the 1,478-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02934555, a Phase 2 study of Cardiac Arrest, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the effects of ubiquinol as a "metabolic resuscitator" in post-cardiac arrest.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Ensure
- DRUG Ubiquinol
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02934555
The ClinicalTrials.gov registry entry for NCT02934555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,478-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (97% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Arrest appearing as the primary indexed condition, and to 2 interventions - of which Ensure is the first listed.
NCT02934555 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02934555 about?
NCT02934555 is a clinical study titled "Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest". To study the effects of ubiquinol as a "metabolic resuscitator" in post-cardiac arrest.
What is the current status of trial NCT02934555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2016-03. Estimated completion is 2019-06-02.
What conditions does trial NCT02934555 study?
This clinical trial studies the following conditions: Cardiac Arrest.
What interventions are being tested in trial NCT02934555?
The interventions under investigation include: Ensure (DIETARY_SUPPLEMENT), Ubiquinol (DRUG).
Who is sponsoring clinical trial NCT02934555?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02934555 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Arrest
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surviving PEA in Roanoke (SPEAR) Study
RECRUITING · Phase 2
-
Early Amiodarone in Shockable Cardiac Arrest
RECRUITING · Phase 3
-
Hospital Airway Resuscitation Trial
RECRUITING · NA
-
Post-CA Neuroprotection With Magnesium
RECRUITING · Phase 1
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Resuscitative TEE Collaborative Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.